Merck's Juvisync Becomes First Fixed-Dose Diabetes/Cholesterol Treatment
This article was originally published in The Pink Sheet Daily
Executive Summary
However, the sitagliptin/simvastatin combination will carry the same price as Januvia, Merck's single-agent sitagliptin component that is still under patent protection.
You may also be interested in...
Merck-Geisinger Collaboration Aims For “Pipeline” Of Treatment Adherence Tools
The first tool that will be developed is an interactive web application designed to help primary care clinicians assess and engage patients at risk for cardiometabolic syndrome.
Statin Labeling Changes Include Class Warning About Glucose Effects
All statin labels now warn that “increases in HbA1C and fasting serum glucose levels have been reported” with the cholesterol-lowering drugs. Labels also reflect a relaxation of hepatic monitoring requirements, which could remove one hurdle to Pfizer’s pursuit of an OTC switch for Lipitor.
Statin Labeling Changes Include Class Warning About Glucose Effects
All statin labels now warn that “increases in HbA1C and fasting serum glucose levels have been reported” with the cholesterol-lowering drugs. Labels also reflect a relaxation of hepatic monitoring requirements, which could remove one hurdle to Pfizer’s pursuit of an OTC switch for Lipitor.